Is the price fair?
What IRMD's price assumes
IRADIMED CORPORATION trades at 47.8× earnings against 33.4× for the median Medical Devices name, more expensive than its own group.
47.8
Trailing P/E · Medical Devices median 33.4 · 1.43× the median: the market pays up for this one
- Price / sales
- 14.3
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.1%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +17%
Growth the price implies · The price pays for +17% free cash flow growth a year for a decade; the business has delivered +58% a year over the last three.
Details›
- Price / book2026-Q1
- 12.6
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $24M
- Market capitalisation
- $1.18B
- 3-year revenue growth
- +15%
- 3-year free cash flow growth
- +58%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $59.12 |
| Its own P/E history, median | $63.99 |
| Its own P/E history, upper quartile | $92.97 |
| 52-week range | $67.77 – $104.87 |
| Today | $87.48 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.